# PT-141 Results in the Studies: Trials, Numbers, and Reviews

> PT-141 results in plain English: the RECONNECT trial outcomes, the 52-week extension, brain-imaging data, and how experts read the size of the bremelanotide benefit.

Every headline number from the bremelanotide trials, read plainly and tied to its source.

## The short version

These are the PT-141 results — the actual numbers the studies measured. In two large trials of premenopausal women with low desire, bremelanotide beat a placebo (dummy injection) on two goals: it raised sexual desire and lowered the distress that low desire caused [3]. The improvement was real and statistically solid, but modest in size — and experts openly debate how meaningful a modest improvement is [10].

A year-long follow-up showed the benefit held up and uncovered no new safety problems [4]. Newer studies are adding mechanism (brain-imaging) and exploring new directions [5][13]. Below, each result is laid out with its number and its citation, so you can see exactly what was found rather than a summary of a summary.

## The RECONNECT trials: the headline numbers

The two pivotal Phase 3 trials, together called RECONNECT, enrolled 1,267 premenopausal women with HSDD. Bremelanotide 1.75 mg, taken as needed, met both coprimary goals: sexual desire (measured on a standardized desire score) rose by +0.35, and desire-related distress fell by -0.33 — each statistically significant (P<.001) against placebo over 24 weeks [3].

Those are the defining results. They are positive and reproducible across two identical trials, which strengthens confidence. They are also modest in absolute terms, which is why the page below on effect size matters. The most common adverse events in the trials were nausea, flushing, and headache [3].

## The 52-week extension: did it last?

Short trials can flatter a drug. The open-label extension followed 684 women for up to 52 weeks to test durability. The desire improvement was sustained, and no new safety signals emerged over the longer period [4].

The extension also gave the clearest long-term tolerability picture: the most common drug-related effects were nausea (40.4%), flushing (20.6%), and headache (12.0%) [4]. Nausea, in other words, was not a transient first-dose nuisance — it remained the principal tolerability issue across a year of use. That honest detail is part of the result, not a footnote to it.

## The brain-imaging result

Beyond the questionnaire scores, a 2022 study measured what happened in the brain. In 31 premenopausal women with HSDD, a single MC4R-activating dose significantly increased sexual desire for up to 24 hours and changed task-based brain processing of erotic images — strengthening amygdala-insula connectivity and engaging cerebellar and motor-planning regions [5].

This result matters because it converts a self-reported score into a measurable brain effect, supporting the central (brain-first) mechanism rather than a placebo story. It is a small study, but a mechanistically important one.

## How big is the benefit, really

The most honest result is about size. An effect-size analysis of HSDD efficacy trials reported that medications including bremelanotide produced a mean effect size of about 1.0 — comparable to psychotherapy — but placebo alone produced a moderate effect of about 0.55 [10]. The gap between drug and placebo is where the real, drug-specific benefit lives, and it is smaller than the headline figure suggests.

That is why critical re-analyses argue the effects on desire and distress, while statistically significant, are small, and question how clinically meaningful they are [7]. None of this erases the benefit — it sizes it. Reading PT-141 results well means holding both ideas: the effect is real, and it is modest.

## PT-141 reviews: how experts summarize it

Formal reviews — the closest thing to vetted PT-141 reviews — place bremelanotide within the broader treatment landscape rather than rating it in isolation. A 2025 review of novel pharmacologic treatments for female sexual dysfunction gives current therapeutic-landscape context for where bremelanotide fits [16], and 2025 conference reports compare it head-to-head with other approved or used options and describe secondary arousal and orgasm signals [14][15].

These expert summaries are the reviews worth weighting. Informal user reviews exist, but they are anecdotal and unverified — they appear, clearly labeled, on the [PT-141 effects](/effects) page, kept separate from the cited trial results here.

---

A plain-English research desk for PT-141 (bremelanotide), reading the newest studies first — the one approved use named, the off-label uses flagged, the modest benefit and the nausea both kept in view; a reading desk, not a clinic, with nothing here dosed or sold.